Regulatory approvals have become an increasingly important enabler for healthcare and medical technology companies seeking to expand into international markets, particularly as demand grows for products that meet established safety, quality and performance standards. In the UK, registration with the Medicines and Healthcare Products Regulatory Agency (MHRA) provides companies with an important regulatory foothold as they look to build market access and strengthen their presence across the country and allied markets. Against this backdrop, Lord’s Mark Industries Limited has secured another regulatory milestone, with its In-Vitro Diagnostic (IVD) portfolio registered with the MHRA, days after announcing the UK registration of its AI-powered Renalyx haemodialysis system, further advancing its plans to establish a broader healthcare and diagnostics presence across the UK and UK-allied markets.
The latest registration, dated September 24, 2026, records Lord’s Mark Industries as a registered manufacturer and covers IVD categories including haematological cell analysers, multiple clinical chemistry analysers, buffered sample diluents and instrument/analyser cleaning agents.
